The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

Item
http://www.wikidata.org/entity/Q57904348
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the lMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTreatment of multiple myeloma bone disease: experimental and clinical data.Novel therapeutic targets in myeloma bone disease.Bone disease in multiple myeloma: pathophysiology and management.Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.Sotatercept in patients with osteolytic lesions of multiple myeloma.Myeloma and Bone Disease.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.Emerging treatment approaches for myeloma-related bone disease.N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.The Proteasome and Myeloma-Associated Bone Disease.Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.
P2860

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

Item
http://www.wikidata.org/entity/Q57904348
description
im Oktober 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2013
@uk
name
The combination of lenalidomid ...... the Greek myeloma study group
@en
The combination of lenalidomid ...... the Greek myeloma study group
@nl
type
label
The combination of lenalidomid ...... the Greek myeloma study group
@en
The combination of lenalidomid ...... the Greek myeloma study group
@nl
prefLabel
The combination of lenalidomid ...... the Greek myeloma study group
@en
The combination of lenalidomid ...... the Greek myeloma study group
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
The combination of lenalidomid ...... the Greek myeloma study group
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921